Article
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2011
Brevet Marie, Johnson Melissa L, Azzoli Christopher G, Ladanyi Marc
Abstract excerpt
AIMS: EGFR mutations now guide the clinical use of EGFR-targeted therapy in lung cancer. However, standard EGFR mutation analysis requires a minimum amount of tumor tissue, which may not be available in certain situations. In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.